Hong Kong-listed Akeso Biopharma (09926.HK) opened nearly 15% lower after its overseas partner, Summit Therapeutics, announced that its application for the marketing authorization of Evoxis had not been approved by the U.S. Food and Drug Administrati

2026-11-16

Hong Kong-listed Akeso Biopharma (09926.HK) opened nearly 15% lower after its overseas partner, Summit Therapeutics, announced that its application for the marketing authorization of Evoxis had not been approved by the U.S. Food and Drug Administration (FDA).